ADAPT Master · ARGX-999-2-MG-2000

Methodological framework for a platform study exploring various therapeutic options and their safety profile in people diagnosed with myasthenia gravis.

A master protocol for an exploratory phase 2a, proof-of-concept platform study assessing the safety, tolerability and efficacy of multiple regimens in participants with myasthenia gravis.

Sponsor: argenx BV

Phase: II

Status: Recruiting

View clinical trials catalogue

Public study eligibility criteria

Inclusion

  • * Is at least 18 years of age and the local legal age of consent for clinical studies
  • * Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
  • * If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening

Exclusion

  • * Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
  • * Is MGFA (Myasthenia Gravis Foundation of America) Class V